These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38898265)

  • 1. The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer.
    Le Guevelou J; Cuccia F; Flippot R; Ferrera G; Terlizzi M; Zilli T; De Crevoisier R; Hannoun-Levi JM; Supiot S; Sargos P; Pasquier D
    Prostate Cancer Prostatic Dis; 2024 Jun; ():. PubMed ID: 38898265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic radiotherapy to oligoprogressive lesions detected with
    Onal C; Ozyigit G; Oymak E; Guler OC; Tilki B; Hurmuz P; Akyol F
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3683-3692. PubMed ID: 33693965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial.
    Zhao X; Wang T; Ye Y; Li J; Gao X; Zhang H
    BMJ Open; 2022 Sep; 12(9):e051371. PubMed ID: 36180115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy.
    Ingrosso G; Detti B; Fodor A; Caini S; Borghesi S; Triggiani L; Trippa F; Russo D; Bruni A; Francolini G; Lancia A; Marinelli L; Di Muzio N; Livi L; Magrini SM; Maranzano E; Musio D; Aristei C; Valeriani M
    Clin Transl Oncol; 2021 Aug; 23(8):1577-1584. PubMed ID: 33495981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
    Onal C; Kose F; Ozyigit G; Aksoy S; Oymak E; Muallaoglu S; Guler OC; Tilki B; Hurmuz P; Akyol F
    Prostate; 2021 Jun; 81(9):543-552. PubMed ID: 33905131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic Body Radiotherapy for Oligoprogression in Castration-Resistant Prostate Cancer: Early Toxicity Analysis of the TRAP Trial.
    Patel PH; Dreibe S; Reid A; Parker C; Murray J; Pathmanathan A; Tirona A; Guevara J; Suh YE; Frew J; Palaniappan N; Syndikus I; Attard G; Tunariu N; Tree AC
    Clin Oncol (R Coll Radiol); 2024 Sep; 36(9):585-592. PubMed ID: 39004535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer.
    Deek MP; Taparra K; Phillips R; Velho PI; Gao RW; Deville C; Song DY; Greco S; Carducci M; Eisenberger M; DeWeese TL; Denmeade S; Pienta K; Paller CJ; Antonarakis ES; Olivier KR; Park SS; Tran PT; Stish BJ
    Eur Urol Oncol; 2021 Jun; 4(3):447-455. PubMed ID: 32536574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients' selection.
    Franzese C; Perrino M; Marzo MA; Badalamenti M; Baldaccini D; D'Agostino G; Marini B; De Vincenzo F; Zucali PA; Scorsetti M
    Clin Exp Metastasis; 2022 Jun; 39(3):449-457. PubMed ID: 35190933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiotherapy to lymph nodes in oligoprogressive castration-resistant prostate cancer patients: a post hoc analysis from two phase I clinical trials.
    Pezzulla D; Macchia G; Cilla S; Buwenge M; Ferro M; Bonome P; Romano C; Zamagni A; Valentini V; Morganti AG; Deodato F
    Clin Exp Metastasis; 2021 Dec; 38(6):519-526. PubMed ID: 34651242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival Outcomes and Pattern of Relapse After SABR for Oligometastatic Prostate Cancer.
    Mercier C; Claessens M; De Troyer B; Debacker T; Fransis K; Vandeursen H; Ost P; Dirix P
    Front Oncol; 2022; 12():863609. PubMed ID: 35494057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.
    Kwon DH; Shakhnazaryan N; Shui D; Hong JC; Mohamad O; de Kouchkovsky I; Borno HT; Bose R; Chou J; Desai A; Fong L; Friedlander TW; Koshkin VS; Aggarwal RR; Feng FY; Hope TA; Small EJ
    Urol Oncol; 2023 Mar; 41(3):145.e7-145.e15. PubMed ID: 36435709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression-free survival in patients with
    Werensteijn-Honingh AM; Wevers AFJ; Peters M; Kroon PS; Intven M; Eppinga WSC; Jürgenliemk-Schulz IM
    Acta Oncol; 2021 Oct; 60(10):1342-1351. PubMed ID: 34323648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer-Prevalence and Current Clinical Practice.
    Patel PH; Tunariu N; Levine DS; de Bono JS; Eeles RA; Khoo V; Murray J; Parker CC; Pathmanathan A; Reid A; van As N; Tree AC
    Front Oncol; 2022; 12():862995. PubMed ID: 35656509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression-directed Therapy in Oligoprogressive Castration-resistant Prostate Cancer: Final Results from the Prospective, Single-arm, Phase 2 MEDCARE Trial.
    Rans K; Joniau S; Berghen C; Goffin K; Dumez H; Haustermans K; De Meerleer G
    Eur Urol Oncol; 2024 Apr; ():. PubMed ID: 38664137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
    Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G
    Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of the efficacy of stereotactic ablative radiotherapy for oligoprogressive disease in metastatic cancer.
    Doyle E; Killean AJ; Harrow S; Phillips ID
    Radiother Oncol; 2024 Jul; 196():110288. PubMed ID: 38648995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.
    Tsai CJ; Yang JT; Shaverdian N; Patel J; Shepherd AF; Eng J; Guttmann D; Yeh R; Gelblum DY; Namakydoust A; Preeshagul I; Modi S; Seidman A; Traina T; Drullinsky P; Flynn J; Zhang Z; Rimner A; Gillespie EF; Gomez DR; Lee NY; Berger M; Robson ME; Reis-Filho JS; Riaz N; Rudin CM; Powell SN;
    Lancet; 2024 Jan; 403(10422):171-182. PubMed ID: 38104577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Review of Stereotactic Body Radiation Therapy in the Management of Oligometastatic Prostate Cancer.
    Zhang B; Leech M
    Anticancer Res; 2020 May; 40(5):2419-2428. PubMed ID: 32366385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-Term Outcomes and Clinical Efficacy of Stereotactic Body Radiation Therapy (SBRT) for Oligometastases of Prostate Cancer in China.
    Xu C; Zhao X; Ju X; Shen Y; Qu M; Ye Y; Wang X; Yu C; Gao X; Zhang H
    Front Oncol; 2022; 12():879310. PubMed ID: 35574331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study.
    Triggiani L; Mazzola R; Magrini SM; Ingrosso G; Borghetti P; Trippa F; Lancia A; Detti B; Francolini G; Matrone F; Bortolus R; Fanetti G; Maranzano E; Pasqualetti F; Paiar F; Bonù ML; Magli A; Bruni A; Mazzeo E; Franzese C; Scorsetti M; Alongi F; Jereczek-Fossa BA; Ost P; Buglione M
    World J Urol; 2019 Dec; 37(12):2631-2637. PubMed ID: 30859273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.